---
layout: post
title: "新冠口服药板块走强背后：诊疗方案现重要调整 三大投资方向跃然眼前"
date: 2022-03-17 17:49:55 +0800
categories: emnews
tags: 东财滚动新闻
---
> 今日(17日)新冠药板块走强，复星医药、精华制药、尖峰集团、华海药业、美诺华、普洛药业、九州药业盘中一度涨停。截至收盘，中国医药涨停，君实生物、博瑞医药、复星医药、精华制药、雅本化学涨超5%。（财联社）

<!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1060" data-code="BK1060|90|1" data-code2="BK1060|90|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1060&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1060_0" data-code="K BK1060|90|1" data-code2="K BK1060|90|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>今日(17日)新冠药板块走强，<span id="stock_1.600196"><a href="http://quote.eastmoney.com/unify/r/1.600196" class="keytip" data-code="1,600196">复星医药</a></span><span id="quote_1.600196"></span>、<span id="stock_0.002349"><a href="http://quote.eastmoney.com/unify/r/0.002349" class="keytip" data-code="0,002349">精华制药</a></span><span id="quote_0.002349"></span>、<span id="stock_1.600668"><a href="http://quote.eastmoney.com/unify/r/1.600668" class="keytip" data-code="1,600668">尖峰集团</a></span><span id="quote_1.600668"></span>、<span id="stock_1.600521"><a href="http://quote.eastmoney.com/unify/r/1.600521" class="keytip" data-code="1,600521">华海药业</a></span><span id="quote_1.600521"></span>、<span id="stock_1.603538"><a href="http://quote.eastmoney.com/unify/r/1.603538" class="keytip" data-code="1,603538">美诺华</a></span><span id="quote_1.603538"></span>、<span id="stock_0.000739"><a href="http://quote.eastmoney.com/unify/r/0.000739" class="keytip" data-code="0,000739">普洛药业</a></span><span id="quote_0.000739"></span>、九州药业盘中一度涨停。截至收盘，<span id="stock_1.600056"><a href="http://quote.eastmoney.com/unify/r/1.600056" class="keytip" data-code="1,600056">中国医药</a></span><span id="quote_1.600056"></span>涨停，<span id="Info.116.01877"><a href="http://quote.eastmoney.com/unify/r/116.01877" class="keytip" data-code="116,01877">君实生物</a></span>、<span id="stock_1.688166"><a href="http://quote.eastmoney.com/unify/r/1.688166" class="keytip" data-code="1,688166">博瑞医药</a></span><span id="quote_1.688166"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600196" class="em_stock_key_common" data-code="1,600196">复星医药</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002349" class="em_stock_key_common" data-code="0,002349">精华制药</span>、<span id="stock_0.300261"><a href="http://quote.eastmoney.com/unify/r/0.300261" class="keytip" data-code="0,300261">雅本化学</a></span><span id="quote_0.300261"></span>涨超5%。</p>
 <center><img src="https://dfscdn.dfcfw.com/download/D24759664000238842812_w620h451.jpg" alt="image" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p>直接催化因素在于，17日有消息称，日内瓦药品专利池(Medicines Patent Pool，MPP)组织宣布，已与35家药企签署协议，允许其生产<span id="stock_106.PFE"><a href="http://quote.eastmoney.com/unify/r/106.PFE" class="keytip" data-code="106,PFE">辉瑞</a></span><span id="quote_106.PFE"></span>新冠口服药Paxlovid成分之一奈玛特韦(Nirmatrelvir)原料药或制剂，包括上海迪赛诺、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600521" class="em_stock_key_common" data-code="1,600521">华海药业</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000739" class="em_stock_key_common" data-code="0,000739">普洛药业</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600196" class="em_stock_key_common" data-code="1,600196">复星医药</span>、<span id="stock_1.603456"><a href="http://quote.eastmoney.com/unify/r/1.603456" class="keytip" data-code="1,603456">九洲药业</a></span><span id="quote_1.603456"></span>这五家中国企业。</p>
 <p>Paxlovid作为<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>原研，是目前全球疗效较好的新冠药。今日涨停的<span web="1" href="http://quote.eastmoney.com/unify/r/1.600056" class="em_stock_key_common" data-code="1,600056">中国医药</span>是Paxlovid在中国大陆的代理商。</p>
 <p><strong>截至发稿，MPP官网尚未公布上述消息，相关药企也无一确认。</strong></p>
 <p><strong>不过，<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>此前已传递出开放授权的信号。</strong>当地时间1月18日，辉瑞发布消息称，已与MPP签署了一项自愿许可协议，以帮助扩大其在95个中低收入国家的可及性，这约占53%的世界人口。但这条消息并未透露涉及哪些企业。</p>
 <p><strong>诊疗方案现重要调整国内厂商积极布局</strong></p>
 <p>目前，奥密克戎毒株已取代德尔塔毒株成为主要流行株，而奥密克戎毒株患者以无症状感染者和轻型病例为主，新冠口服药为重要治疗手段。鉴于此，国内未来新冠的防治思路正发生变化。</p>
 <p>15日晚间，国家卫健委发布《新型冠状病毒肺炎诊疗方案(试行第九版)》，<strong>辉瑞的口服药Paxlovid和腾盛博药的安巴韦单抗/罗米司韦单抗一起被写入了推荐治疗方案。除此以外，两会也提出要加速新冠药物的研发。</strong></p>
 <p>与此同时，国内药企在口服药上的进展令人期待，3月以来已有多家公司发声，披露阶段性成果：</p>
 <p><strong><span web="1" href="http://quote.eastmoney.com/unify/r/116.01877" class="em_stock_key_common" data-code="116,01877">君实生物</span></strong>16日宣布与旺山旺水合作开发的新冠口服药VV116一期数据“令人满意”，已启动三期临床研究；<strong>开拓药业</strong>相关负责人近日在接受媒体采访时表示，目前普克鲁胺治疗新冠的三个全球多中心三期临床试验正积极推进中，将在2022年3月下旬最迟不晚于4月上旬公布顶线数据。</p>
 <p><strong><span web="1" href="http://quote.eastmoney.com/unify/r/1.603538" class="em_stock_key_common" data-code="1,603538">美诺华</span></strong>15日披露了“年产60吨抗新冠药奈玛特韦原料药及其关键中间体新建项目”备案通过的相关事项，计划新增SM1产能90吨，SM2产能120吨，该公司目前已交付5吨SM1和10吨SM2，并有几十吨订单在洽谈。<strong>《科创板日报》记者今日致电<span web="1" href="http://quote.eastmoney.com/unify/r/1.603538" class="em_stock_key_common" data-code="1,603538">美诺华</span><span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>部，公司人士表示，“不能透露客户单位，但公司确实是在MPP供应链上的。”其还透露，订单洽谈进展顺利。</strong></p>
 <p><strong>三大投资方向跃然眼前</strong></p>
 <p>具体到投资机会，综合多位<span id="Info.3224"><a href="http://data.eastmoney.com/invest/invest/default.html" class="infokey">分析师</a></span>观点，主要分三大方向：<strong>获海外仿制药MPP授权的企业、进度靠前的国内研发创新企业、新冠药产业链上游潜在供应商。</strong></p>
 <p>东莞<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>分析师魏红梅表示，未来国产新冠小分子药有望上市，整体市场前景较为广阔。建议关注新冠小分子药研发进度较快的<span web="1" href="http://quote.eastmoney.com/unify/r/116.01877" class="em_stock_key_common" data-code="116,01877">君实生物</span>；深度参与全球新冠小分子供应链的CDMO企业<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>、<span id="stock_0.002821"><a href="http://quote.eastmoney.com/unify/r/0.002821" class="keytip" data-code="0,002821">凯莱英</a></span><span id="quote_0.002821"></span>、<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>等。</p>
 <p>民生<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>分析师周超泽预计，MPP<span id="Info.3332"><a href="http://data.eastmoney.com/notices/" class="infokey">公告</a></span>Paxlovid仿制药厂商将于近期落地，全球庞大的市场将给中国的API企业带来产业链供应机会，目前上游关键中间体仍然处于较高的价格水平，有相关技术和产能储备的公司有望带来良好的利润弹性，建议关注<span id="stock_0.002453"><a href="http://quote.eastmoney.com/unify/r/0.002453" class="keytip" data-code="0,002453">华软科技</a></span><span id="quote_0.002453"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600521" class="em_stock_key_common" data-code="1,600521">华海药业</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603456" class="em_stock_key_common" data-code="1,603456">九洲药业</span>、<span id="stock_0.002001"><a href="http://quote.eastmoney.com/unify/r/0.002001" class="keytip" data-code="0,002001">新和成</a></span><span id="quote_0.002001"></span>、<span id="stock_0.300233"><a href="http://quote.eastmoney.com/unify/r/0.300233" class="keytip" data-code="0,300233">金城医药</a></span><span id="quote_0.300233"></span>、<span id="stock_0.300003"><a href="http://quote.eastmoney.com/unify/r/0.300003" class="keytip" data-code="0,300003">乐普医疗</a></span><span id="quote_0.300003"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.000739" class="em_stock_key_common" data-code="0,000739">普洛药业</span>等。</p>
 <p><span id="stock_1.601878"><a href="http://quote.eastmoney.com/unify/r/1.601878" class="keytip" data-code="1,601878">浙商证券</a></span><span id="quote_1.601878"></span>分析师孙建发布<span id="Info.3319"><a href="http://data.eastmoney.com/report/" class="infokey">研报</a></span>称，海外新冠特效药中间体、原料药有望成为全球性大吨位品种，中国原料药及CDMO公司基于较强的合成技术、较完备的化工配套和先进产能优势，部分公司有望持续获益于全球产业分工下的新冠特效药供应链。CDMO方面，推荐<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002821" class="em_stock_key_common" data-code="0,002821">凯莱英</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300363" class="em_stock_key_common" data-code="0,300363">博腾股份</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.603456" class="em_stock_key_common" data-code="1,603456">九洲药业</span>、普洛药业等公司；原料药方面，建议关注<span id="stock_0.300702"><a href="http://quote.eastmoney.com/unify/r/0.300702" class="keytip" data-code="0,300702">天宇股份</a></span><span id="quote_0.300702"></span>、华海药业、<span id="stock_1.605116"><a href="http://quote.eastmoney.com/unify/r/1.605116" class="keytip" data-code="1,605116">奥锐特</a></span><span id="quote_1.605116"></span>、<span id="stock_1.603229"><a href="http://quote.eastmoney.com/unify/r/1.603229" class="keytip" data-code="1,603229">奥翔药业</a></span><span id="quote_1.603229"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688166" class="em_stock_key_common" data-code="1,688166">博瑞医药</span>等公司。</p><p class="em_media">（文章来源：财联社）</p>

<http://stock.eastmoney.com/news/1406,202203172314091766.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)